2025 AAISG Annual Meeting

May 2, 2025 to May 4, 2025

The 2025 AAISG Annual Meeting is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Society of Georgia (AAISG).  
The 2025 program will provide evidence-based, clinical topics that address major aspects of attendees' practices and will provide attendees exposure to new content.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Society of Georgia (AAISG).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commerical support was received for this activity.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…
1.    Discuss pro/cons of risks of OIT with use of biologic medications.
2.    Discuss and understand updated asthma guidelines & therapies.
3.    Understand and manage the difficult diagnosis of pruritus.
4.    Manage the diverse topic of dermatitis.
5.    Understand current advocacy issues.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Course opens: 
05/02/2025
Course expires: 
12/31/2026
Event starts: 
05/02/2025 - 6:00pm CDT
Event ends: 
05/04/2025 - 12:30pm CDT
Add to calendar: 
Rating: 
0

2025 AAISG Annual Meeting
Lake Lanier Legacy Lodge
Buford GA

May 2-4, 2025

Friday, May 2, 2025

6:00 pm–7:00 pm

Cocktails and Registration (non-CME)

Grand Ballroom A

7:00 pm–7:50 pm

Betty Wray Lecture and Dinner: Future of Food Allergy | Brian Vickery, CPC

Grand Ballroom A

7:50 pm–8:00 pm

Q & A Session     

Grand Ballroom A

8:00 pm–9:00 pm

Social Networking Time (non-CME)

Grand Ballroom A

Saturday, May 3, 2025

7:00 am–8:00 am

Breakfast (non-CME)

Grand Ballroom B&C

8:00 am–8:50 am

Dermatitis I Luz Fonacier, MD

Veranda Room

8:50 am–9:00 am

Q & A Session

Veranda Room

9:00 am–9:17 am

Fellow-In-Training MCG Presentation – School Absenteeism Among Rural Adolescents with Asthma I Tyesha Coleman, MD

Veranda Room

9:18 am–9:20 am

Q & A Session     

Veranda Room

9:20 am–9:37 am

Fellow-In-Training MCG Presentation -Delayed Diagnosis of X-Linked Agammaglobulinemia with Novel BTK Variant I Adam Prevot, MD

Veranda Room

9:38 am–9:40 am

Q & A Session

Veranda Room

9:40 am–10:00 am

Break (non-CME)               

Grand Ballroom B&C       

10:00 am–10:50 am

Pruritus I Luz Fonacier, MD

Veranda Room

10:50 am–11:00 am

Q & A Session

Veranda Room

11:00 am–11:50 pm

Asthma phenotypes I Mario Castro, MD

Veranda Room

11:50 pm–12:00 pm

Q & A Session

Veranda Room

12:00 pm–12:17 pm

Fellow-in-Training MCG Presentation A case of cold urticaria vs familial cold autoinflammatory syndrome in a patient with a novel NLRC4 variant | Hye Yoon, MD

Veranda Room

12:18 pm–12:20 pm         

Q & A Session     

Veranda Room

12:20 pm–12:40 pm

Business Meeting (All members encouraged to attend) (non-CME)

Veranda Room

12:20 pm–1:10 pm

Lunch (non-CME)

Grand Ballroom B&C

1:10 pm–1:30 pm

Emory Clinical Research (Non-CME presentation) I Brian Vickery MD

Veranda Room

1:30 pm–2:30 pm

Anti-TSLP Medications (non-CME Presentation) - TBA

Veranda Room

7:00 pm–10:00 pm                                            

Dinner and Entertainment (non-CME)

Blue Ridge A-C

Sunday, May 4, 2025       

7:00 am–8:00 am

Breakfast (non-CME)

Grand Ballroom B&C

8:00 am–8:50 am

Asthma 2024 GINA guidelines |Richard Bickel MD

Veranda Room

8:50 am–9:00 am

Q & A Session

Veranda Room

9:00 am–9:17 am              

Fellow-In-Training Emory Presentation – Case Report: Systemic mastocytosis with KIT mutation in an infant with asymptomatic urticaria pigmentosa | Wendy Bao, MD

Veranda Room

9:18 am–9:20 am

Q & A Session

Veranda Room

9:20 am–9:37 am

Fellow-In-Training Emory Presentation – The use of elevated ferritin levels in neonates and young infants as a screening lab for hemophagocytic lymphohistiocytosis | Jessica Feng, MD

Veranda Room

9:38 am–9:40 am

Q & A Session     

Veranda Room

9:40 am–10:00 am

Break (non-CME)

Grand Ballroom B&C

10:00 am-10:50 am

Advocacy and Regulatory Issues in Allergy I Melinda Rathkopf, MD (Brought to You by The American College of Allergy, Asthma, & Immunology

Veranda Room

10:50 am–11:00 am

Q & A Session

Veranda Room

11:00 am–11:17 am

Fellow-In-Training Emory Presentation – X-Linked-Lymphoproliferative-Syndrome in a Child Presenting for Eosinophilic Gastritis | Kelly Cronin, MD

Veranda Room

11:18 am–11:20 am

Q & A Session

Veranda Room

11:20 am–12:20 pm

Lunch (non-CME)

Grand Ballroom B&C

11:20 am–12:20 pm

Inhibiting IL-4 and IL-13 Signaling Across Five Diseases (non-CME Presentation) | TBA

Veranda Room

12:30 pm

Adjourn

Veranda Room

All relevant financial relationships with ineligible companies have been mitigated.

Rodney Johnson, MD, Planner, Program Chair
Speaker: AstraZeneca

Mario Castro, MD, Speaker
Researcher: AstraZeneca, Gala Therapeutics, Genentech, GSK, Nocion, Novartis, Pulmatrix, Sanofi/Aventis, Theravance Biopharma
Consultant: Allakos, Amgen, Apogee, Apreo Health, Arrowhead Pharmaceuticals, AstraZeneca, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Jasper, Kinaset, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, Sanofi-Aventis, Teva, Third Rock Ventures, Upstream Bio, Verona Pharmaceuticals
Speaker: Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., Sanofi-Aventis
Stock/Options: Aer Therapeutics

Luz Fonacier, MD, Speaker
Advisor: Regeneron, Pfizer, Abbvie, Eli Lilly, Leo, Dermavent
Researcher: Regeneron, Pfizer

Brian Vickery, MD, Speaker
Researcher: Aravax, DBV, Regeneron, Genentech, AstraZeneca, Siolta
Advisor: Genentech, Reacta 
Stock/Options: Moonlight

The following have no relevant financial relationships with ineligible companies to disclose:

Gerald Lee, MD, Planner
Jennifer Shih, MD, Planner
Wendy Bao, MD, Speaker
Richard Bickel, MD, Speaker
Tyesha Coleman, MD, Speaker
Kelly Cronin, MD, Speaker
Jessica Feng, MD, Speaker
Adam Prevot, MD, Speaker
Melinda Rathkopf, MD, Speaker
Hye Young Yoon, MD, Speaker

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Please login or create an account to take this course.

Note